FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132132020> ?p ?o ?g. }

• W3132132020 endingPage "06" @default.
• W3132132020 startingPage "GS3" @default.
• W3132132020 abstract "Abstract Background: Trophoblast cell-surface antigen-2 (Trop-2) is highly expressed in many epithelial tumors, including triple-negative breast cancer (TNBC). Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38, an active metabolite of irinotecan, via a unique hydrolyzable linker that allows for SN-38 release intracellularly and in the tumor microenvironment (bystander effect). Preclinical studies have shown a great range of efficacy with SG in mice bearing tumors with low, moderate, and high Trop-2 expression levels. We report subgroup analyses by Trop-2 expression from ASCENT, a randomized, phase 3 confirmatory study of SG versus standard-of-care chemotherapy in patients with metastatic TNBC (mTNBC). Methods: In the global, multicenter, open-label, phase 3 ASCENT study (NCT02574455), 529 patients with mTNBC refractory to or relapsing after at least 2 prior chemotherapies were randomized 1:1 to receive SG (10 mg/kg intravenously on days 1 and 8 every 21 days) or single-agent treatment of physician’s choice (capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) measured by central independent review per RECIST v1.1. Secondary endpoints included objective response rate (ORR) per RECIST v1.1, duration of response, overall survival (OS), and safety. Exploratory endpoints included biomarker assessments, including Trop-2 and BRCA1/2. Trop-2 expression was assessed using a validated immunohistochemistry assay. Results: Subgroup analyses by biomarker expression including Trop-2 and BRCA1/2 were performed, and outcomes by PFS, OS, ORR, and safety results will be reported. Conclusions: These analyses will provide further insights into the relationship of Trop-2 expression and the activity of SG in previously treated patients with mTNBC. Citation Format: Sara A. Hurvitz, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamiltion, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, Tiffany Traina, Joyce O'Shaughnessy, Javier Cortés, Michaela Tsai, Linda Vahdat, Véronique Diéras, Lisa Carey, Hope S. Rugo, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Aditya Bardia. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr GS3-06." @default.
• W3132132020 created "2021-03-01" @default.
• W3132132020 creator A5003890903 @default.
• W3132132020 creator A5019041034 @default.
• W3132132020 creator A5024524838 @default.
• W3132132020 creator A5032459330 @default.
• W3132132020 creator A5032577731 @default.
• W3132132020 creator A5034765349 @default.
• W3132132020 creator A5034972183 @default.
• W3132132020 creator A5038095983 @default.
• W3132132020 creator A5039200681 @default.
• W3132132020 creator A5041912334 @default.
• W3132132020 creator A5051629490 @default.
• W3132132020 creator A5052268581 @default.
• W3132132020 creator A5053983312 @default.
• W3132132020 creator A5055781858 @default.
• W3132132020 creator A5056565799 @default.
• W3132132020 creator A5056927697 @default.
• W3132132020 creator A5058791215 @default.
• W3132132020 creator A5060143828 @default.
• W3132132020 creator A5061549536 @default.
• W3132132020 creator A5064885323 @default.
• W3132132020 creator A5068059897 @default.
• W3132132020 creator A5069056507 @default.
• W3132132020 creator A5073884605 @default.
• W3132132020 creator A5076949146 @default.
• W3132132020 creator A5078388793 @default.
• W3132132020 creator A5079469365 @default.
• W3132132020 creator A5090188675 @default.
• W3132132020 date "2021-02-15" @default.
• W3132132020 modified "2023-10-18" @default.
• W3132132020 title "Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer" @default.
• W3132132020 doi "https://doi.org/10.1158/1538-7445.sabcs20-gs3-06" @default.
• W3132132020 hasPublicationYear "2021" @default.
• W3132132020 type Work @default.
• W3132132020 sameAs 3132132020 @default.
• W3132132020 citedByCount "6" @default.
• W3132132020 countsByYear W31321320202021 @default.
• W3132132020 countsByYear W31321320202022 @default.
• W3132132020 countsByYear W31321320202023 @default.
• W3132132020 crossrefType "journal-article" @default.
• W3132132020 hasAuthorship W3132132020A5003890903 @default.
• W3132132020 hasAuthorship W3132132020A5019041034 @default.
• W3132132020 hasAuthorship W3132132020A5024524838 @default.
• W3132132020 hasAuthorship W3132132020A5032459330 @default.
• W3132132020 hasAuthorship W3132132020A5032577731 @default.
• W3132132020 hasAuthorship W3132132020A5034765349 @default.
• W3132132020 hasAuthorship W3132132020A5034972183 @default.
• W3132132020 hasAuthorship W3132132020A5038095983 @default.
• W3132132020 hasAuthorship W3132132020A5039200681 @default.
• W3132132020 hasAuthorship W3132132020A5041912334 @default.
• W3132132020 hasAuthorship W3132132020A5051629490 @default.
• W3132132020 hasAuthorship W3132132020A5052268581 @default.
• W3132132020 hasAuthorship W3132132020A5053983312 @default.
• W3132132020 hasAuthorship W3132132020A5055781858 @default.
• W3132132020 hasAuthorship W3132132020A5056565799 @default.
• W3132132020 hasAuthorship W3132132020A5056927697 @default.
• W3132132020 hasAuthorship W3132132020A5058791215 @default.
• W3132132020 hasAuthorship W3132132020A5060143828 @default.
• W3132132020 hasAuthorship W3132132020A5061549536 @default.
• W3132132020 hasAuthorship W3132132020A5064885323 @default.
• W3132132020 hasAuthorship W3132132020A5068059897 @default.
• W3132132020 hasAuthorship W3132132020A5069056507 @default.
• W3132132020 hasAuthorship W3132132020A5073884605 @default.
• W3132132020 hasAuthorship W3132132020A5076949146 @default.
• W3132132020 hasAuthorship W3132132020A5078388793 @default.
• W3132132020 hasAuthorship W3132132020A5079469365 @default.
• W3132132020 hasAuthorship W3132132020A5090188675 @default.
• W3132132020 hasConcept C121608353 @default.
• W3132132020 hasConcept C126322002 @default.
• W3132132020 hasConcept C143998085 @default.
• W3132132020 hasConcept C185592680 @default.
• W3132132020 hasConcept C203092338 @default.
• W3132132020 hasConcept C2776694085 @default.
• W3132132020 hasConcept C2778239845 @default.
• W3132132020 hasConcept C2779984678 @default.
• W3132132020 hasConcept C2780110267 @default.
• W3132132020 hasConcept C2780258809 @default.
• W3132132020 hasConcept C2780259306 @default.
• W3132132020 hasConcept C2780350996 @default.
• W3132132020 hasConcept C2781190966 @default.
• W3132132020 hasConcept C2781197716 @default.
• W3132132020 hasConcept C31760486 @default.
• W3132132020 hasConcept C526805850 @default.
• W3132132020 hasConcept C530470458 @default.
• W3132132020 hasConcept C535046627 @default.
• W3132132020 hasConcept C55493867 @default.
• W3132132020 hasConcept C71924100 @default.
• W3132132020 hasConceptScore W3132132020C121608353 @default.
• W3132132020 hasConceptScore W3132132020C126322002 @default.
• W3132132020 hasConceptScore W3132132020C143998085 @default.
• W3132132020 hasConceptScore W3132132020C185592680 @default.
• W3132132020 hasConceptScore W3132132020C203092338 @default.
• W3132132020 hasConceptScore W3132132020C2776694085 @default.
• W3132132020 hasConceptScore W3132132020C2778239845 @default.
• W3132132020 hasConceptScore W3132132020C2779984678 @default.
• W3132132020 hasConceptScore W3132132020C2780110267 @default.
• W3132132020 hasConceptScore W3132132020C2780258809 @default.

• next